vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Reservoir Media, Inc. (RSVR). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $45.6M, roughly 1.6× Reservoir Media, Inc.). Reservoir Media, Inc. runs the higher net margin — 4.8% vs -121.9%, a 126.7% gap on every dollar of revenue. On growth, Reservoir Media, Inc. posted the faster year-over-year revenue change (7.7% vs -6.2%). Reservoir Media, Inc. produced more free cash flow last quarter ($12.8M vs $9.6M). Over the past eight quarters, Reservoir Media, Inc.'s revenue compounded faster (7.9% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Reservoir Media, Inc. is a leading global independent music rights management company. It owns and administers extensive catalogs of recorded music, music publishing copyrights, and neighboring rights, partnering with top songwriters, performing artists, and producers across genres including pop, hip-hop, rock, and film soundtracks. It licenses its content for use across streaming platforms, advertising, film and television productions, live events, and other commercial channels, with operations spanning North America, Europe, and Asia Pacific markets.

HCAT vs RSVR — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.6× larger
HCAT
$74.7M
$45.6M
RSVR
Growing faster (revenue YoY)
RSVR
RSVR
+13.9% gap
RSVR
7.7%
-6.2%
HCAT
Higher net margin
RSVR
RSVR
126.7% more per $
RSVR
4.8%
-121.9%
HCAT
More free cash flow
RSVR
RSVR
$3.2M more FCF
RSVR
$12.8M
$9.6M
HCAT
Faster 2-yr revenue CAGR
RSVR
RSVR
Annualised
RSVR
7.9%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
HCAT
HCAT
RSVR
RSVR
Revenue
$74.7M
$45.6M
Net Profit
$-91.0M
$2.2M
Gross Margin
64.5%
Operating Margin
-115.3%
22.7%
Net Margin
-121.9%
4.8%
Revenue YoY
-6.2%
7.7%
Net Profit YoY
-340.3%
-58.1%
EPS (diluted)
$-1.29
$0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
RSVR
RSVR
Q4 25
$74.7M
$45.6M
Q3 25
$76.3M
$45.4M
Q2 25
$80.7M
$37.2M
Q1 25
$79.4M
$41.4M
Q4 24
$79.6M
$42.3M
Q3 24
$76.4M
$40.7M
Q2 24
$75.9M
$34.3M
Q1 24
$74.7M
$39.1M
Net Profit
HCAT
HCAT
RSVR
RSVR
Q4 25
$-91.0M
$2.2M
Q3 25
$-22.2M
$2.3M
Q2 25
$-41.0M
$-555.7K
Q1 25
$-23.7M
$2.7M
Q4 24
$-20.7M
$5.2M
Q3 24
$-14.7M
$185.0K
Q2 24
$-13.5M
$-346.7K
Q1 24
$-20.6M
$2.8M
Gross Margin
HCAT
HCAT
RSVR
RSVR
Q4 25
64.5%
Q3 25
52.6%
63.6%
Q2 25
64.5%
Q1 25
65.6%
Q4 24
64.4%
Q3 24
47.5%
63.5%
Q2 24
61.3%
Q1 24
63.4%
Operating Margin
HCAT
HCAT
RSVR
RSVR
Q4 25
-115.3%
22.7%
Q3 25
-22.9%
23.5%
Q2 25
-46.0%
14.7%
Q1 25
-25.4%
25.2%
Q4 24
-22.0%
22.6%
Q3 24
-17.9%
24.9%
Q2 24
-20.8%
14.5%
Q1 24
-30.5%
22.4%
Net Margin
HCAT
HCAT
RSVR
RSVR
Q4 25
-121.9%
4.8%
Q3 25
-29.1%
5.0%
Q2 25
-50.8%
-1.5%
Q1 25
-29.9%
6.4%
Q4 24
-26.0%
12.4%
Q3 24
-19.3%
0.5%
Q2 24
-17.8%
-1.0%
Q1 24
-27.6%
7.1%
EPS (diluted)
HCAT
HCAT
RSVR
RSVR
Q4 25
$-1.29
$0.03
Q3 25
$-0.32
$0.03
Q2 25
$-0.59
$-0.01
Q1 25
$-0.35
Q4 24
$-0.33
$0.08
Q3 24
$-0.24
Q2 24
$-0.23
$-0.01
Q1 24
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
RSVR
RSVR
Cash + ST InvestmentsLiquidity on hand
$95.7M
$20.6M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$373.6M
Total Assets
$502.6M
$941.9M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
RSVR
RSVR
Q4 25
$95.7M
$20.6M
Q3 25
$91.5M
$27.9M
Q2 25
$97.3M
$14.9M
Q1 25
$342.0M
$21.4M
Q4 24
$392.0M
$17.8M
Q3 24
$387.3M
$21.1M
Q2 24
$308.3M
$16.4M
Q1 24
$327.8M
$18.1M
Total Debt
HCAT
HCAT
RSVR
RSVR
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
RSVR
RSVR
Q4 25
$245.8M
$373.6M
Q3 25
$331.9M
$370.9M
Q2 25
$347.5M
$368.9M
Q1 25
$376.8M
$364.9M
Q4 24
$365.2M
$359.5M
Q3 24
$355.0M
$357.9M
Q2 24
$357.0M
$353.0M
Q1 24
$357.2M
$353.0M
Total Assets
HCAT
HCAT
RSVR
RSVR
Q4 25
$502.6M
$941.9M
Q3 25
$587.1M
$903.5M
Q2 25
$616.2M
$857.0M
Q1 25
$891.5M
$865.1M
Q4 24
$858.9M
$832.4M
Q3 24
$813.0M
$778.2M
Q2 24
$691.7M
$768.2M
Q1 24
$695.1M
$783.5M
Debt / Equity
HCAT
HCAT
RSVR
RSVR
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
RSVR
RSVR
Operating Cash FlowLast quarter
$9.9M
$12.9M
Free Cash FlowOCF − Capex
$9.6M
$12.8M
FCF MarginFCF / Revenue
12.9%
28.1%
Capex IntensityCapex / Revenue
0.4%
0.3%
Cash ConversionOCF / Net Profit
5.89×
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$50.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
RSVR
RSVR
Q4 25
$9.9M
$12.9M
Q3 25
$-464.0K
$19.3M
Q2 25
$-9.0M
$6.0M
Q1 25
$280.0K
$12.2M
Q4 24
$-3.5M
$11.2M
Q3 24
$6.2M
$13.3M
Q2 24
$1.6M
$8.6M
Q1 24
$10.3M
$13.8M
Free Cash Flow
HCAT
HCAT
RSVR
RSVR
Q4 25
$9.6M
$12.8M
Q3 25
$-719.0K
$19.2M
Q2 25
$-9.2M
$6.0M
Q1 25
$-390.0K
$12.2M
Q4 24
$-3.9M
$11.2M
Q3 24
$5.5M
$13.3M
Q2 24
$1.3M
$8.5M
Q1 24
$10.1M
$13.8M
FCF Margin
HCAT
HCAT
RSVR
RSVR
Q4 25
12.9%
28.1%
Q3 25
-0.9%
42.2%
Q2 25
-11.4%
16.1%
Q1 25
-0.5%
29.3%
Q4 24
-4.9%
26.5%
Q3 24
7.2%
32.7%
Q2 24
1.7%
24.9%
Q1 24
13.5%
35.2%
Capex Intensity
HCAT
HCAT
RSVR
RSVR
Q4 25
0.4%
0.3%
Q3 25
0.3%
0.3%
Q2 25
0.3%
0.1%
Q1 25
0.8%
0.1%
Q4 24
0.5%
0.0%
Q3 24
0.9%
0.1%
Q2 24
0.4%
0.1%
Q1 24
0.3%
0.0%
Cash Conversion
HCAT
HCAT
RSVR
RSVR
Q4 25
5.89×
Q3 25
8.54×
Q2 25
Q1 25
4.56×
Q4 24
2.14×
Q3 24
71.97×
Q2 24
Q1 24
4.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

RSVR
RSVR

Other$18.9M42%
Recorded Music Segment$12.9M28%
Performance$6.2M14%
Synchronization$4.6M10%
Physical$1.9M4%
Neighboring Rights$1.1M3%

Related Comparisons